Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Teplizumab in moderate to severe psoriasis
NCT00954915Phase 2Terminated
- Sponsor
- MacroGenics
- Start
- Dec 2009
- Primary completion
- Jul 2010
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of teplizumab in psoriasis, sponsored by MacroGenics. Started Dec 2009; status: terminated.
02
Drugs
teplizumab
03
Conditions
psoriasis
Beyond the preview
Go deeper on NCT00954915.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00954915.